Ultragenyx Pharmaceutical Inc

2026. szept. 28. 20:07 UTC

Ultragenyx Pharmaceutical Inc shares fell amid a broad market decline driven by rising crude oil prices and inflation concerns, continuing four sessions of negative performance.

2026. szept. 25. 20:02 UTC

Ultragenyx Pharmaceutical Inc shares fell sharply, continuing a four-session decline, aligning with broader challenges in the biotechnology sector.

2026. szept. 24. 20:08 UTC

Ultragenyx Pharmaceutical Inc's shares are declining, settling near the lower end of their one-month range and below the 20-day moving average.

2026. szept. 23. 20:03 UTC

Ultragenyx Pharmaceutical Inc. shares fell sharply amid an investigation by Bronstein, Gewirtz & Grossman, LLC, following disappointing Phase 3 Aspire study results.

2026. szept. 22. 20:03 UTC

Ultragenyx Pharmaceutical Inc. shares are sharply higher following the FDA's approval of Fayuvi for Sanfilippo syndrome Type A and Barclays raising its price target to $35.

2026. szept. 21. 20:07 UTC

Ultragenyx Pharmaceutical Inc's stock rose after Barclays and Morgan Stanley raised price targets, and Fayuvi GTx received approval for treating MPSIIIA.

2026. szept. 18. 20:03 UTC

Ultragenyx Pharmaceutical Inc. gained ground today after FDA approval for FAYUVI, its first treatment for Sanfilippo syndrome type A, despite ongoing investigations.

2026. szept. 17. 23:06 UTC

Ultragenyx Pharmaceutical Inc. gained FDA approval for Fayuvi, the first gene therapy for Sanfilippo syndrome type A, driving after-market trading higher.

2026. szept. 16. 20:10 UTC

Ultragenyx Pharmaceutical Inc shares fell to a new 52-week low as investors reacted to an upcoming FDA decision on UX111, expected by September 19.

2026. szept. 15. 20:03 UTC

Ultragenyx Pharmaceutical is under investigation amid ongoing concerns following disappointing Phase 3 study results, contributing to a decline in share value.

2026. szept. 14. 20:03 UTC

Ultragenyx Pharmaceutical is under investigation, contributing to a decline in shares today, despite receiving FDA orphan designation for GNE myopathy treatment.

2026. szept. 11. 20:09 UTC

Ultragenyx Pharmaceutical shares are lower as Bronstein, Gewirtz & Grossman, LLC, initiates an investigation following disappointing Phase 3 study results for apazunersen.

2026. szept. 10. 20:07 UTC

Ultragenyx Pharmaceutical Inc shares are higher during Thursday's session, fluctuating between a low of -1.28% and a high of 1.96%. No specific news was identified.

2026. szept. 9. 20:02 UTC

Ultragenyx Pharmaceutical shares are declining as an investigation is initiated following the failure of its Phase 3 Aspire study for apazunersen.

2026. szept. 8. 20:04 UTC

Ultragenyx shares are lower after its Phase 3 Aspire trial for apazunersen failed to meet endpoints, prompting expense reductions and mixed analyst ratings.

2026. szept. 4. 20:02 UTC

Ultragenyx Pharmaceutical shares are higher today amid analyst updates, including Goldman Sachs lowering its price target to $19 and Barclays to $32.

2026. szept. 3. 20:03 UTC

Ultragenyx Pharmaceutical's stock is lower after its Phase 3 Aspire trial failed to meet primary endpoints, prompting analyst downgrades and expense reduction plans.

2026. szept. 2. 23:02 UTC

Ultragenyx Pharmaceutical shares are lower in after-market hours following the failure of its Phase 3 Aspire study for apazunersen in Angelman syndrome.

2026. szept. 1. 23:01 UTC

Ultragenyx Pharmaceutical Inc shares are lower in after-market trading despite positive Phase 3 data for GENGLYCOS, reflecting investor caution on FDA approval.

2026. aug. 31. 21:02 UTC

Ultragenyx Pharmaceutical Inc shares are lower in after-market hours, with no specific news identified. Broader market sentiment remains cautious amid Fed rate hike concerns.

2026. aug. 28. 22:56 UTC

Ultragenyx Pharmaceutical Inc. shares are higher in after-market trading, though they remain below their 20-day moving average after recent declines.

2026. aug. 26. 20:08 UTC

Ultragenyx Pharmaceutical granted 45,984 restricted stock units to new non-executive officers as part of its Employment Inducement Plan. Shares are trading roughly flat.

2026. aug. 25. 23:16 UTC

Ultragenyx Pharmaceutical granted nearly 46,000 restricted stock units to new hires, boosting shares in after-market trading amid ongoing strategic initiatives for rare diseases.

2026. aug. 24. 23:16 UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, reflecting a modest increase since Monday's close amid no specific news to explain the movement.

2026. aug. 22. 00:02 UTC

Ultragenyx Pharmaceutical shares are lower in after-market hours, with no specific news identified. The broader market has shown notable gains.

2026. aug. 21. 23:11 UTC

Ultragenyx Pharmaceutical shares moved higher in after-market trading, reflecting broader market gains despite the absence of specific company news.

2026. aug. 20. 23:46 UTC

Ultragenyx Pharmaceutical Inc. shares are higher in after-market trading, showing modest gains since Thursday's close, despite no specific news identified.

2026. aug. 19. 23:51 UTC

Ultragenyx Pharmaceutical received FDA accelerated approval for its gene therapy GENGLYCOS, leading shares to rise sharply in after-market hours.

2026. aug. 18. 23:26 UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market hours. No specific news was identified to explain the price movement.

2026. aug. 17. 23:51 UTC

Ultragenyx Pharmaceutical Inc shares rose in after-market trading, gaining traction despite broader market volatility from geopolitical tensions and rising crude oil prices.